Skip to main content

Rybelsus® 14 mg vs. Victoza® 1.8 mg vs. Placebo (PIONEER 4 Study)

This video discusses the trial-design and outcomes of the PIONEER 4 study. PIONEER 4 was a 52-week, phase 3a, randomized, double-blind, double-dummy, active- and placebo-controlled, multinational trial in 711 adults with type 2 diabetes.

Play
Pause
Skip
Volume
Chapters
Transcript
References
video_su
Fullscreen

Rybelsus® 14 mg vs. Victoza® 1.8 mg vs. Placebo (PIONEER 4 Study)

Chapters
Transcript
References

Return to overview

Transcripts

Return to overview

References